Literature DB >> 370002

Steroids, aspirin, and inflammation.

E Katler, G Weissmann.   

Abstract

The ability of adrenal corticosteroids to both both suppress inflammation and compromise host defenses has been well documented. Recently, a series of in vitro and in vivo experiments, based on our new knowledge of the cell biology of inflammation and the biochemistry of the phagocytic cell itself, has provided new insights into the mechanism of steroid action in the inflammatory process. Evidence is presented that pharmacologic doses of steroids are capable of inhibiting each of the steps in phagocytic-micro-organism interaction: chemotaxis, recognition and opsonization, phagocytosis, membrane fusion, and degranulation. In addition, steroid alteration of the postphagocytic superoxide production, hydrogen peroxide generation, and prostaglandin and thromboxane synthesis is described. The antiinflammatory effects of aspirin and indomethacin can be explained almost entirely by virtue of their ability to inhibit cyclooxygenase, this preventing the transformation of arachidonic acid to both prostaglandins and thromboxanes. The cortisol-induced inhibition of endoperoxides, prostaglandins, and thromboxanes (at a site proximal to the release of arachidonic acid) may well explain those antiinflammatory actions that cortisone shares with aspirin. However, patients treated with nonsteroidal antiinflammatory agents effectively combat infections. In contrast, corticosteroids have more profound effects, as can be seen by the inhibition of superoxide production, with the subsequent decrease in hydrogen peroxide generation and the diminution in release of the antibacterial lysosomal hydrolases within the phagocytic vacuole. Thus, corticosteroids interfere with the killing of microorganisms. This new understanding of the pharmacologic action of cortisol on phagocytic cells explains, we believe, how glucocorticoids alleviate inflammation while, at the same time, they permit multiplication of the offending microorganism within the phagocyte.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 370002     DOI: 10.1007/bf00921009

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  42 in total

1.  Influence of corticosteroids on human polymorphonuclear leukocyte function in vitro : Reduction of lysosomal enzyme release and superoxide production.

Authors:  I M Goldstein; D Roos; G Weissmann; H B Kaplan
Journal:  Inflammation       Date:  1976-06       Impact factor: 4.092

2.  Leukocyte chemotaxis in vivo. II. Analysis of the selective inhibition of neutrophil or mononuclear cell accumulation.

Authors:  R J Perper; M Sanda; G Chinea; A L Oronsky
Journal:  J Lab Clin Med       Date:  1974-09

3.  Prostaglandin E1: effect on human cutaneous vasculature and skin histamine.

Authors:  J Sondergaard; M W Greaves
Journal:  Br J Dermatol       Date:  1971-05       Impact factor: 9.302

4.  Effects of anti-inflammatory drugs on prostaglandin biosynthesis.

Authors:  R Flower; R Gryglewski; K Herbaczyńska-Cedro; J R Vane
Journal:  Nat New Biol       Date:  1972-07-26

5.  Bacteriuria in rheumatoid arthritis.

Authors:  H C Burry
Journal:  Ann Rheum Dis       Date:  1973-05       Impact factor: 19.103

6.  Site of action of cortisol in cellular immunity.

Authors:  W L Weston; H N Claman; G G Krueger
Journal:  J Immunol       Date:  1973-03       Impact factor: 5.422

7.  The in vitro effect of steroids on polymorphonuclear leukocyte metabolism.

Authors:  M R Cooper; L R DeChatelet; C E McCall
Journal:  Proc Soc Exp Biol Med       Date:  1972-12

8.  Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea-pig lungs.

Authors:  M A Palmer; P J Piper; J R Vane
Journal:  Br J Pharmacol       Date:  1973-10       Impact factor: 8.739

9.  Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.

Authors:  S Moncada; E A Higgs; J R Vane
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

10.  Effects of corticosteroids on human monocyte function.

Authors:  J J Rinehart; S P Balcerzak; A L Sagone; A F LoBuglio
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

View more
  7 in total

1.  Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura.

Authors:  Liang Zheng; Yingying Mao; Mohammad S Abdelgawwad; Nicole K Kocher; Mandy Li; Xiangrong Dai; Benjamin Li; X Long Zheng
Journal:  Blood Adv       Date:  2016-11-29

2.  Effect of indomethacin on the incidence of experimental Escherichia coli pyelonephritis.

Authors:  M P Glauser; P B Francioli; J Bille; M Bonard; P Meylan
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

3.  Prostaglandin E2 suppresses the differentiation of retinoic acid-producing dendritic cells in mice and humans.

Authors:  Angus Stock; Sarah Booth; Vincenzo Cerundolo
Journal:  J Exp Med       Date:  2011-03-28       Impact factor: 14.307

4.  Dexamethasone modulates Salmonella enterica serovar Typhimurium infection in vivo independently of the glucocorticoid-inducible protein annexin-A1.

Authors:  Tomoko Smyth; Sabine Tötemeyer; Sean Haugland; Chrissie Willers; Sarah Peters; Duncan Maskell; Clare Bryant
Journal:  FEMS Immunol Med Microbiol       Date:  2008-12

Review 5.  The standard of care for immune thrombotic thrombocytopenic purpura today.

Authors:  X Long Zheng
Journal:  J Thromb Haemost       Date:  2021-06-30       Impact factor: 16.036

6.  Impact of anti-inflammatory drug consumption in peritonsillar abscesses: a retrospective cohort study.

Authors:  Thomas Feasson; Mathilde Debeaupte; Clément Bidet; Florence Ader; François Disant; Tristan Ferry; Christian Chidiac; Florent Valour
Journal:  BMC Infect Dis       Date:  2016-08-20       Impact factor: 3.090

7.  A retrospective analysis of commonly prescribed medications and the risk of developing breast cancer related lymphedema.

Authors:  Eelco Fj Meijer; Echoe M Bouta; Clive Mendonca; Melissa N Skolny; Laura W Salama; Alphonse G Taghian; Timothy P Padera
Journal:  Clin Res Trials       Date:  2020-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.